A comparison of fetal-loss reports in the Vaccine Adverse Event Reporting
System (VAERS) during three consecutive influenza seasons shows there was a
synergistic toxicity causing spontaneous abortions (SAB) and stiillbirths (SB)
following the Center for Disease Control (CDC) recommendations of pandemic and
influenza vaccines administered to pregnant women.
An overwhelming majority of pregnant women who visit the doctor's office are
now refusing the flu vaccine over fears it will harm their fetus and their
fears are now scientifically justified. More than 90% of all expecting mothers
will now say no to the flu vaccine due to fear of miscarriage and delivery of
toxic byproducts to their unborn child.
In 2011, Dr. Alessandro Bertoucci who analyzed the practices of 256 physicians
treating more than 600,000 patients, reported that a staggering 91% of pregnant
women are declining influenza vaccines due to fears of miscarriage and suspected
toxins in the vaccine itself.
A study published last year in the Human and Experimental Toxicology journal
found a direct statistical correlation between higher vaccine doses and infant
mortality rates. It was a confirmation that many anti-vaccine advocates have
long awaited and further establishes and adds to preliminary evidence that
vaccinations are toxic poisons having no place in the human body.
The study,
Infant mortality rates regressed against number of vaccine doses routinely
given: Is there a biochemical or synergistic toxicity?, was conducted by
Gary S. Goldman and Neil Z. Miller who has been studying the dangers of vaccines
for 25 years.
The infant mortality rate (IMR) is one of the most important indicators of the
socio-economic well-being and public health conditions of a country. The US
childhood immunization schedule specifies 26 vaccine doses for infants aged less
than 1 year--the most in the world--yet 33 nations have lower IMRs. Australia
and Canada are a close 2nd and 3rd respectively with 24 vaccine doses.
Some countries have IMRs that are less than half the US rate: Singapore, Sweden,
and Japan are examples. According to the Centers for Disease Control and
Prevention (CDC), "The relative position of the United States in comparison to
countries with the lowest infant mortality rates appears to be worsening."
Goldman's most recent study
Comparison of VAERS fetal-loss reports during three consecutive influenza
seasons successfully correlated fetal toxicity resulting from the
administration of both the pandemic (A-H1N1) and seasonal influenza vaccines
during the 2009/10 season.
Since 1997, the Advisory Committee on Immunization Practices (ACIP) has
recommended the routine vaccination of pregnant women with trivalent inactivated
influenza vaccine (TIV) after the first trimester of pregnancy. This
recommendation was expanded in 2004 to include all trimesters of pregnancy.
All previously published studies of pregnant women who were administered TIV
have reported this vaccine as safe during all stages of pregnancy.
Frequently cited peer-reviewed reports on the safety of influenza
vaccination during pregnancy do not reveal any adverse outcomes among women.
Many of these studies, used "no Thimerosal" influenza vaccines, had insufficient
statistical power to adequately detect and assess complications due to the small
sample size.
In another follow-up safety study (conducted among 2,291 pregnant women) cited
by ACIP did not find increased childhood mortality associated with
exposure to TIV in pregnancy. However, fetallosses were not included in
the analysis as found in
critical assessments of the study.
The safety and effectiveness of the pandemic (monovalent influenza) A-H1N1
vaccine had not been previously established in pregnant women. Nor was the
combination of two different influenza vaccines ever tested in pregnant women.
The A-H1N1 vaccine inserts from the various manufacturers contained this
caution: "It is also not known whether these vaccines can cause fetal harm when
administered to pregnant women or can affect reproduction capacity."
In October 2010, Moro et al summarized that during 19 influenza seasons (1990/91
through 2008/09) there were a total of 17 spontaneous abortion (SAB) and 6
stillbirth (SB) reports following TIV in VAERS database.
An
independent survey was conducted by the
National Coalition of Organized Women (NCOW) via the Internet to serve as a
second surveillance source for pregnant women suffering A-H1N1 fetal loss during
the two-vaccine 2009/10 influenza season. Eileen Dannemann, director of NCOW,
oversaw this study and the data collected are summarized in the Results section.
In response to a public service announcement delivered via several websites on
the Internet, respondents contacted one of two study coordinators via phone or
e-mail address. The respondents provided relevant details including (a) type of
influenza vaccine received, (b) date of vaccination, (c) type of vaccine, (d)
date of onset of symptom(s), (e) date of spontaneous abortion or miscarriage,
(f) geographic location, (g) whether or not the adverse event was reported to
VAERS, and (h) other miscellaneous comments.
Results from Goldman's study shows that although there was an approximate 4-fold
(43%/11.3%) increase in the percentage of pregnant women vaccinated in 2009/10
compared to 2008/09, there was a 43.5-fold increase in fetal-loss reports--from
4 in 2008/09 to 174 in 2009/10.
Based on respondents' comments to the NCOW survey in the 2009/10 season, it is
likely that the ascertainment-corrected rate of 535 fetal losses per million
pregnant women vaccinated represents a significant underestimate during the
two-vaccine 2009/10 influenza season since healthcare professionals explained to
patients "the benefits of influenza vaccination outweighed the risks." Medical
literature reporting the mean rate of "1.9 fetal losses per million pregnant
women vaccinated" for the previous 19 single-vaccine influenza seasons based on
counts of VAERS reports that were not adjusted for under-ascertainment, likely
contributed to this perception of safety. Because both patient and healthcare
professionals relied on a historical profile that was incomplete with respect to
assessing fetal-demise reporting, a possible link to fetal demise following
administration of influenza vaccine(s) during 2009/10 was rarely contemplated or
was considered highly unlikely and thus, more often than not, not reported.
When one or more Thimerosal-containing vaccines, including some formulations of
the seasonal TIV and pandemic monovalent A-H1N1 vaccines are administered to a
pregnant woman, the fetus is also indirectly exposed to mercury.
The linkage between Thimerosal and neurodevelopmental disorders is a concern
because
several studies have shown that children with autistic spectrum disorders (ASDs)
have higher levels of mercury body burden than typically developing children. In
addition, there is a positive correlation between mercury body burden and
severity of ASD symptoms. Direct measurement of injury in the brains of children
with ASD reinforce this finding; there is a significant dose-dependent positive
correlation between oxidative stress markers (evidence of brain injury) and
mercury levels in the brains of children with ASD.
The amount of mercury that accumulates in any given fetus and the severity of
its impact depend upon several factors in addition to the maternal mercury
exposure due to injected Thimerosal-containing inactivated-influenza vaccines.
Dental amalgams in pregnant woman contribute to increased mercury burden in the
developing fetus and newborn. Also, the maternal-fetal genetic background can
modulate fetal exposure to mercury; thus, certain gene variants influence
mercury toxicokinetics causing the variable susceptibility that is observed with
respect to mercury toxicity. This variation in genetic susceptibility, combined
with factors of diet and antibiotic use, can synergistically enhance mercury
toxicity and effectively preclude establishment of a safe mercury dosing level
for all individuals.
Moreover, the 0.1 mcg/kg-day reference dose that the Environmental Protection
Agency (EPA) established as safe based on oral ingestion of mercury is not
applicable for injected Thimerosal via vaccination since injection bypasses the
absorption protection provided by the gastrointestinal system intestines (which
is also apparently dependent on the manner in which the fish or other
mercury-containing food is prepared), thereby delivering more of the toxic dose
of mercury administered into the body.
Thus, it is biologically plausible that during the two-vaccine 2009/10 influenza
season, when pregnant women were administered two Thimerosal-containing
influenza vaccines each delivering 50 mcg of Thimerosal (or 25 mcg of mercury
per dose), the fetus' mercury dose exceeded the EPAs reference (oral) dose for
oral exposure of (0.1 mcg of mercury/kg-day). This over-exposure could be a
significant contributing factor to some of the reported SABs and SBs. Moreover,
the mercury in injected Thimerosal-containing vaccine doses has been found to
preferentially bioaccumulate in the fetal tissues.
The study concluded that the concomitant administration of the seasonal
influenza and pandemic A-H1N1 vaccines during 2009/10, suggests a synergistic
toxicity and a statistically significant higher rate of fetal loss reporting
relative to the single-dose seasons.
The VAERS rates of 6.8 and 12.6 fetal-loss reports per million women vaccinated
for those single-vaccine seasons may provide healthcare professionals with a
sense that influenza vaccines administered during pregnancy are relatively safe,
when, in reality, these rates merely reflect the low level of case ascertainment
associated with VAERS and thus, grossly underestimate the true rates encountered
in the U.S. population. Just because a single vaccine has been tested and
considered safe, does not imply there will not be a synergistic fetal toxicity
effect associated with the administration of two or more Thimerosal-containing
vaccines to a pregnant woman and/or a synergistic toxicity effect from the
combination of the biologically active components contained in concomitantly
administered vaccines.
In addition, because of the order of magnitude increase in fetal-loss report
rates, from 6.8 fetal-loss reports per million pregnant woman vaccinated in the
1-dose 2008/09 season to 77.8 in the 2-dose 2009/10 season, further long-term
studies are needed to assess adverse outcomes in the surviving children.
Additional research concerning the risk factors associated with the potential
synergistic toxicity associated with the administration of Thimerosal-containing
vaccines is warranted and the exposure-effect association should be verified in
further toxicological and case-control studies.
Sources:
Comparison of VAERS fetal-loss reports during three consecutive influenza
seasons
Progressive Convergence
scribd.com
Dave Mihalovic is a Naturopathic Doctor who specializes in vaccine research, cancer prevention and a natural approach to treatment.